Click for best price
Drugs for Neuromyelitis Optica Market Size, Share 2023
| Market size in 2022 |
US$ 48 million
|
Forecast Market size by 2029 |
US$ 61 million
|
| Growth Rate |
CAGR of 3.3% |
Number of Pages |
70 Pages |
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
This report aims to provide a comprehensive presentation of the global market for Drugs for Neuromyelitis Optica, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Neuromyelitis Optica. This report contains market size and forecasts of Drugs for Neuromyelitis Optica in global, including the following market information:
Global Drugs for Neuromyelitis Optica Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Drugs for Neuromyelitis Optica Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Drugs for Neuromyelitis Optica companies in 2022 (%)
The global Drugs for Neuromyelitis Optica market was valued at US$ 48 million in 2022 and is projected to reach US$ 61 million by 2029, at a CAGR of 3.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
We surveyed the Drugs for Neuromyelitis Optica manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Neuromyelitis Optica Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Drugs for Neuromyelitis Optica Market Segment Percentages, by Type, 2022 (%)
Glucocorticoids
Immunotherapies
Other
Global Drugs for Neuromyelitis Optica Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Drugs for Neuromyelitis Optica Market Segment Percentages, by Application, 2022 (%)
Acute Attack
Remission Prophylactic Treatment
Global Drugs for Neuromyelitis Optica Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Drugs for Neuromyelitis Optica Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Neuromyelitis Optica revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drugs for Neuromyelitis Optica revenues share in global market, 2022 (%)
Key companies Drugs for Neuromyelitis Optica sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Drugs for Neuromyelitis Optica sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Neuromyelitis Optica, market overview.
Chapter 2: Global Drugs for Neuromyelitis Optica market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Neuromyelitis Optica manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Neuromyelitis Optica in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Neuromyelitis Optica capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Drugs for Neuromyelitis Optica Market, Global Outlook and Forecast 2023-2030 |
| Market size in 2022 |
US$ 48 million
|
| Forecast Market size by 2029 |
US$ 61 million
|
| Growth Rate |
CAGR of 3.3% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
70 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Neuromyelitis Optica Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Neuromyelitis Optica Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Neuromyelitis Optica Overall Market Size
2.1 Global Drugs for Neuromyelitis Optica Market Size: 2022 VS 2030
2.2 Global Drugs for Neuromyelitis Optica Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Drugs for Neuromyelitis Optica Sales: 2018-2030
3 Company Landscape
3.1 Top Drugs for Neuromyelitis Optica Players in Global Market
3.2 Top Global Drugs for Neuromyelitis Optica Companies Ranked by Revenue
3.3 Global Drugs for Neuromyelitis Optica Revenue by Companies
3.4 Global Drugs for Neuromyelitis Optica Sales by Companies
3.5 Global Drugs for Neuromyelitis Optica Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Drugs for Neuromyelitis Optica Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Drugs for Neuromyelitis Optica Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drugs for Neuromyelitis Optica Players in Global Market
3.8.1 List of Global Tier 1 Drugs for Neuromyelitis Optica Companies
3.8.2 List of Global Tier 2 and Tier 3 Drugs for Neuromyelitis Optica Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Neuromyelitis Optica Market Size Markets, 2022 & 2030
4.1.2 Glucocorticoids
4.1.3 Immunotherapies
4.1.4 Other
4.2 By Type - Global Drugs for Neuromyelitis Optica Revenue & Forecasts
4.2.1 By Type - Global Drugs for Neuromyelitis Optica Revenue, 2018-2023
4.2.2 By Type - Global Drugs for Neuromyelitis Optica Revenue, 2024-2030
4.2.3 By Type - Global Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
4.3 By Type - Global Drugs for Neuromyelitis Optica Sales & Forecasts
4.3.1 By Type - Global Drugs for Neuromyelitis Optica Sales, 2018-2023
4.3.2 By Type - Global Drugs for Neuromyelitis Optica Sales, 2024-2030
4.3.3 By Type - Global Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
4.4 By Type - Global Drugs for Neuromyelitis Optica Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Neuromyelitis Optica Market Size, 2022 & 2030
5.1.2 Acute Attack
5.1.3 Remission Prophylactic Treatment
5.2 By Application - Global Drugs for Neuromyelitis Optica Revenue & Forecasts
5.2.1 By Application - Global Drugs for Neuromyelitis Optica Revenue, 2018-2023
5.2.2 By Application - Global Drugs for Neuromyelitis Optica Revenue, 2024-2030
5.2.3 By Application - Global Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
5.3 By Application - Global Drugs for Neuromyelitis Optica Sales & Forecasts
5.3.1 By Application - Global Drugs for Neuromyelitis Optica Sales, 2018-2023
5.3.2 By Application - Global Drugs for Neuromyelitis Optica Sales, 2024-2030
5.3.3 By Application - Global Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
5.4 By Application - Global Drugs for Neuromyelitis Optica Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Drugs for Neuromyelitis Optica Market Size, 2022 & 2030
6.2 By Region - Global Drugs for Neuromyelitis Optica Revenue & Forecasts
6.2.1 By Region - Global Drugs for Neuromyelitis Optica Revenue, 2018-2023
6.2.2 By Region - Global Drugs for Neuromyelitis Optica Revenue, 2024-2030
6.2.3 By Region - Global Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
6.3 By Region - Global Drugs for Neuromyelitis Optica Sales & Forecasts
6.3.1 By Region - Global Drugs for Neuromyelitis Optica Sales, 2018-2023
6.3.2 By Region - Global Drugs for Neuromyelitis Optica Sales, 2024-2030
6.3.3 By Region - Global Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Drugs for Neuromyelitis Optica Revenue, 2018-2030
6.4.2 By Country - North America Drugs for Neuromyelitis Optica Sales, 2018-2030
6.4.3 US Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.4.4 Canada Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.4.5 Mexico Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Drugs for Neuromyelitis Optica Revenue, 2018-2030
6.5.2 By Country - Europe Drugs for Neuromyelitis Optica Sales, 2018-2030
6.5.3 Germany Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.5.4 France Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.5.5 U.K. Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.5.6 Italy Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.5.7 Russia Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.5.8 Nordic Countries Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.5.9 Benelux Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Drugs for Neuromyelitis Optica Revenue, 2018-2030
6.6.2 By Region - Asia Drugs for Neuromyelitis Optica Sales, 2018-2030
6.6.3 China Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.6.4 Japan Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.6.5 South Korea Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.6.6 Southeast Asia Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.6.7 India Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Drugs for Neuromyelitis Optica Revenue, 2018-2030
6.7.2 By Country - South America Drugs for Neuromyelitis Optica Sales, 2018-2030
6.7.3 Brazil Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.7.4 Argentina Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Drugs for Neuromyelitis Optica Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Drugs for Neuromyelitis Optica Sales, 2018-2030
6.8.3 Turkey Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.8.4 Israel Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.8.5 Saudi Arabia Drugs for Neuromyelitis Optica Market Size, 2018-2030
6.8.6 UAE Drugs for Neuromyelitis Optica Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Drugs for Neuromyelitis Optica Major Product Offerings
7.1.4 Pfizer Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Fresenius
7.2.1 Fresenius Company Summary
7.2.2 Fresenius Business Overview
7.2.3 Fresenius Drugs for Neuromyelitis Optica Major Product Offerings
7.2.4 Fresenius Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.2.5 Fresenius Key News & Latest Developments
7.3 Teva
7.3.1 Teva Company Summary
7.3.2 Teva Business Overview
7.3.3 Teva Drugs for Neuromyelitis Optica Major Product Offerings
7.3.4 Teva Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.3.5 Teva Key News & Latest Developments
7.4 Sandoz
7.4.1 Sandoz Company Summary
7.4.2 Sandoz Business Overview
7.4.3 Sandoz Drugs for Neuromyelitis Optica Major Product Offerings
7.4.4 Sandoz Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.4.5 Sandoz Key News & Latest Developments
7.5 Intas
7.5.1 Intas Company Summary
7.5.2 Intas Business Overview
7.5.3 Intas Drugs for Neuromyelitis Optica Major Product Offerings
7.5.4 Intas Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.5.5 Intas Key News & Latest Developments
7.6 Gyjtrs
7.6.1 Gyjtrs Company Summary
7.6.2 Gyjtrs Business Overview
7.6.3 Gyjtrs Drugs for Neuromyelitis Optica Major Product Offerings
7.6.4 Gyjtrs Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.6.5 Gyjtrs Key News & Latest Developments
7.7 NANG KUANG
7.7.1 NANG KUANG Company Summary
7.7.2 NANG KUANG Business Overview
7.7.3 NANG KUANG Drugs for Neuromyelitis Optica Major Product Offerings
7.7.4 NANG KUANG Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.7.5 NANG KUANG Key News & Latest Developments
7.8 Tianjin Kingyork
7.8.1 Tianjin Kingyork Company Summary
7.8.2 Tianjin Kingyork Business Overview
7.8.3 Tianjin Kingyork Drugs for Neuromyelitis Optica Major Product Offerings
7.8.4 Tianjin Kingyork Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.8.5 Tianjin Kingyork Key News & Latest Developments
7.9 Baxter
7.9.1 Baxter Company Summary
7.9.2 Baxter Business Overview
7.9.3 Baxter Drugs for Neuromyelitis Optica Major Product Offerings
7.9.4 Baxter Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.9.5 Baxter Key News & Latest Developments
7.10 CSL
7.10.1 CSL Company Summary
7.10.2 CSL Business Overview
7.10.3 CSL Drugs for Neuromyelitis Optica Major Product Offerings
7.10.4 CSL Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.10.5 CSL Key News & Latest Developments
7.11 Grifols
7.11.1 Grifols Company Summary
7.11.2 Grifols Drugs for Neuromyelitis Optica Business Overview
7.11.3 Grifols Drugs for Neuromyelitis Optica Major Product Offerings
7.11.4 Grifols Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.11.5 Grifols Key News & Latest Developments
7.12 Octapharma
7.12.1 Octapharma Company Summary
7.12.2 Octapharma Drugs for Neuromyelitis Optica Business Overview
7.12.3 Octapharma Drugs for Neuromyelitis Optica Major Product Offerings
7.12.4 Octapharma Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.12.5 Octapharma Key News & Latest Developments
7.13 CBOP
7.13.1 CBOP Company Summary
7.13.2 CBOP Drugs for Neuromyelitis Optica Business Overview
7.13.3 CBOP Drugs for Neuromyelitis Optica Major Product Offerings
7.13.4 CBOP Drugs for Neuromyelitis Optica Sales and Revenue in Global (2018-2023)
7.13.5 CBOP Key News & Latest Developments
8 Global Drugs for Neuromyelitis Optica Production Capacity, Analysis
8.1 Global Drugs for Neuromyelitis Optica Production Capacity, 2018-2030
8.2 Drugs for Neuromyelitis Optica Production Capacity of Key Manufacturers in Global Market
8.3 Global Drugs for Neuromyelitis Optica Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drugs for Neuromyelitis Optica Supply Chain Analysis
10.1 Drugs for Neuromyelitis Optica Industry Value Chain
10.2 Drugs for Neuromyelitis Optica Upstream Market
10.3 Drugs for Neuromyelitis Optica Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drugs for Neuromyelitis Optica Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Drugs for Neuromyelitis Optica in Global Market
Table 2. Top Drugs for Neuromyelitis Optica Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Drugs for Neuromyelitis Optica Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Drugs for Neuromyelitis Optica Revenue Share by Companies, 2018-2023
Table 5. Global Drugs for Neuromyelitis Optica Sales by Companies, (K Units), 2018-2023
Table 6. Global Drugs for Neuromyelitis Optica Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Drugs for Neuromyelitis Optica Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Drugs for Neuromyelitis Optica Product Type
Table 9. List of Global Tier 1 Drugs for Neuromyelitis Optica Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Neuromyelitis Optica Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Drugs for Neuromyelitis Optica Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Drugs for Neuromyelitis Optica Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Drugs for Neuromyelitis Optica Sales (K Units), 2018-2023
Table 15. By Type - Global Drugs for Neuromyelitis Optica Sales (K Units), 2024-2030
Table 16. By Application ? Global Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Drugs for Neuromyelitis Optica Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Drugs for Neuromyelitis Optica Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Drugs for Neuromyelitis Optica Sales (K Units), 2018-2023
Table 20. By Application - Global Drugs for Neuromyelitis Optica Sales (K Units), 2024-2030
Table 21. By Region ? Global Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Drugs for Neuromyelitis Optica Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Drugs for Neuromyelitis Optica Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Drugs for Neuromyelitis Optica Sales (K Units), 2018-2023
Table 25. By Region - Global Drugs for Neuromyelitis Optica Sales (K Units), 2024-2030
Table 26. By Country - North America Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Drugs for Neuromyelitis Optica Sales, (K Units), 2018-2023
Table 29. By Country - North America Drugs for Neuromyelitis Optica Sales, (K Units), 2024-2030
Table 30. By Country - Europe Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Drugs for Neuromyelitis Optica Sales, (K Units), 2018-2023
Table 33. By Country - Europe Drugs for Neuromyelitis Optica Sales, (K Units), 2024-2030
Table 34. By Region - Asia Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Drugs for Neuromyelitis Optica Sales, (K Units), 2018-2023
Table 37. By Region - Asia Drugs for Neuromyelitis Optica Sales, (K Units), 2024-2030
Table 38. By Country - South America Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Drugs for Neuromyelitis Optica Sales, (K Units), 2018-2023
Table 41. By Country - South America Drugs for Neuromyelitis Optica Sales, (K Units), 2024-2030
Table 42. By Country - Middle East & Africa Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Drugs for Neuromyelitis Optica Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Drugs for Neuromyelitis Optica Sales, (K Units), 2024-2030
Table 46. Pfizer Company Summary
Table 47. Pfizer Drugs for Neuromyelitis Optica Product Offerings
Table 48. Pfizer Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Fresenius Company Summary
Table 51. Fresenius Drugs for Neuromyelitis Optica Product Offerings
Table 52. Fresenius Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Fresenius Key News & Latest Developments
Table 54. Teva Company Summary
Table 55. Teva Drugs for Neuromyelitis Optica Product Offerings
Table 56. Teva Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Teva Key News & Latest Developments
Table 58. Sandoz Company Summary
Table 59. Sandoz Drugs for Neuromyelitis Optica Product Offerings
Table 60. Sandoz Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Sandoz Key News & Latest Developments
Table 62. Intas Company Summary
Table 63. Intas Drugs for Neuromyelitis Optica Product Offerings
Table 64. Intas Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Intas Key News & Latest Developments
Table 66. Gyjtrs Company Summary
Table 67. Gyjtrs Drugs for Neuromyelitis Optica Product Offerings
Table 68. Gyjtrs Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Gyjtrs Key News & Latest Developments
Table 70. NANG KUANG Company Summary
Table 71. NANG KUANG Drugs for Neuromyelitis Optica Product Offerings
Table 72. NANG KUANG Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. NANG KUANG Key News & Latest Developments
Table 74. Tianjin Kingyork Company Summary
Table 75. Tianjin Kingyork Drugs for Neuromyelitis Optica Product Offerings
Table 76. Tianjin Kingyork Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Tianjin Kingyork Key News & Latest Developments
Table 78. Baxter Company Summary
Table 79. Baxter Drugs for Neuromyelitis Optica Product Offerings
Table 80. Baxter Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Baxter Key News & Latest Developments
Table 82. CSL Company Summary
Table 83. CSL Drugs for Neuromyelitis Optica Product Offerings
Table 84. CSL Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. CSL Key News & Latest Developments
Table 86. Grifols Company Summary
Table 87. Grifols Drugs for Neuromyelitis Optica Product Offerings
Table 88. Grifols Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Grifols Key News & Latest Developments
Table 90. Octapharma Company Summary
Table 91. Octapharma Drugs for Neuromyelitis Optica Product Offerings
Table 92. Octapharma Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Octapharma Key News & Latest Developments
Table 94. CBOP Company Summary
Table 95. CBOP Drugs for Neuromyelitis Optica Product Offerings
Table 96. CBOP Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. CBOP Key News & Latest Developments
Table 98. Drugs for Neuromyelitis Optica Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 99. Global Drugs for Neuromyelitis Optica Capacity Market Share of Key Manufacturers, 2021-2023
Table 100. Global Drugs for Neuromyelitis Optica Production by Region, 2018-2023 (K Units)
Table 101. Global Drugs for Neuromyelitis Optica Production by Region, 2024-2030 (K Units)
Table 102. Drugs for Neuromyelitis Optica Market Opportunities & Trends in Global Market
Table 103. Drugs for Neuromyelitis Optica Market Drivers in Global Market
Table 104. Drugs for Neuromyelitis Optica Market Restraints in Global Market
Table 105. Drugs for Neuromyelitis Optica Raw Materials
Table 106. Drugs for Neuromyelitis Optica Raw Materials Suppliers in Global Market
Table 107. Typical Drugs for Neuromyelitis Optica Downstream
Table 108. Drugs for Neuromyelitis Optica Downstream Clients in Global Market
Table 109. Drugs for Neuromyelitis Optica Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Drugs for Neuromyelitis Optica Segment by Type in 2022
Figure 2. Drugs for Neuromyelitis Optica Segment by Application in 2022
Figure 3. Global Drugs for Neuromyelitis Optica Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Drugs for Neuromyelitis Optica Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Drugs for Neuromyelitis Optica Revenue, 2018-2030 (US$, Mn)
Figure 7. Drugs for Neuromyelitis Optica Sales in Global Market: 2018-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Drugs for Neuromyelitis Optica Revenue in 2022
Figure 9. By Type - Global Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
Figure 11. By Type - Global Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
Figure 12. By Type - Global Drugs for Neuromyelitis Optica Price (US$/Unit), 2018-2030
Figure 13. By Application - Global Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
Figure 15. By Application - Global Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
Figure 16. By Application - Global Drugs for Neuromyelitis Optica Price (US$/Unit), 2018-2030
Figure 17. By Region - Global Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Drugs for Neuromyelitis Optica Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
Figure 20. By Region - Global Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
Figure 21. By Country - North America Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
Figure 22. By Country - North America Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
Figure 23. US Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
Figure 28. Germany Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 29. France Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
Figure 37. China Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 41. India Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
Figure 43. By Country - South America Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
Figure 44. Brazil Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Drugs for Neuromyelitis Optica Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Drugs for Neuromyelitis Optica Sales Market Share, 2018-2030
Figure 48. Turkey Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Drugs for Neuromyelitis Optica Revenue, (US$, Mn), 2018-2030
Figure 52. Global Drugs for Neuromyelitis Optica Production Capacity (K Units), 2018-2030
Figure 53. The Percentage of Production Drugs for Neuromyelitis Optica by Region, 2022 VS 2030
Figure 54. Drugs for Neuromyelitis Optica Industry Value Chain
Figure 55. Marketing Channels
